The deadline is July 31, 2026
The titration schedules commonly used with Retatrutide accomplish something similar, even if not formally designed for that purpose
Although early trial results are encouraging, retatrutide is not yet approved for use in the UK or elsewhere
At Rivas Medical Weight Loss, patient safety and high-quality care are paramount
Half-life refers to the amount of time it takes for 50% of a compound to leave the bloodstream
China GLP-1 Receptor Agonist Market Analysis The China GLP-1 receptor agonist market was valued at USD 2.35 billion in 2025, supported by rapid emergence of domestic peptide drug developers, increasing government support for innovative biologics under national healthcare reforms, and expanding local manufacturing capacity for metabolic therapies